Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Maria G G TektonidouGkikas KatsifisAthanasios GeorgountzosAthina TheodoridouEftychia-Maria KoukliAnna KandiliGiasna Giokic-KakavouliTheofilos-Diamantis KaratsourakisPublished in: Therapeutic advances in musculoskeletal disease (2020)
Adalimumab improves work productivity and sleep problems while lowering disease activity in patients with moderate to severe RA, PsA, and AS managed in real-world settings.
Keyphrases
- disease activity
- ankylosing spondylitis
- rheumatoid arthritis
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- systemic lupus erythematosus
- climate change
- sleep quality
- prostate cancer
- physical activity
- mental health
- interstitial lung disease
- high intensity
- hidradenitis suppurativa
- ulcerative colitis
- systemic sclerosis